

## DAFTAR PUSTAKA

- Aihara, M. (2011). Pharmacogenetics of cutaneous adverse drug reactions. *The Journal of Dermatology*, 38(3), 246–254. <https://doi.org/10.1111/j.1346-8138.2010.01196.x>
- Bharadwaj, M., Illing, P., Theodossis, A., Purcell, A. W., Rossjohn, J., & McCluskey, J. (2012). Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. *Annual Review of Pharmacology and Toxicology*, 52, 401–431. <https://doi.org/10.1146/annurev-pharmtox-010611-134701>
- Chiu, M. L. S., Hu, M., Ng, M. H. L., Yeung, C. K., Chan, J. C. Y., Chang, M. M., ... Tomlinson, B. (2012). Association between HLA-B\*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. *The British Journal of Dermatology*, 167(1), 44–49. <https://doi.org/10.1111/j.1365-2133.2012.10894.x>
- Chohan, S. (2011). Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. *The Journal of Rheumatology*, 38(9), 1957–1959. <https://doi.org/10.3899/jrheum.110092>
- Chung, W.-H., Wang, C.-W., & Dao, R.-L. (2016). Severe cutaneous adverse drug reactions. *The Journal of Dermatology*, 43(7), 758–766. <https://doi.org/10.1111/1346-8138.13430>
- Dean, L. (2012). Allopurinol Therapy and HLA-B\*58:01 Genotype. In V. Pratt, H. McLeod, W. Rubinstein, L. Dean, B. Kattman, & A. Malheiro (eds.), *Medical Genetics Summaries*. Bethesda (MD): National Center for Biotechnology Information (US).
- Fernando, S. L., & Broadfoot, A. J. (2010). Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. *Canadian Medical Association Journal*, 182(5), 476–480. <https://doi.org/10.1503/cmaj.090401>
- FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., ... Neogi, T. (2020). 2020 american college of rheumatology guideline for the management of gout. *Arthritis Care & Research*, 72(6), 744–760. <https://doi.org/10.1002/acr.24180>
- Hershfield, M. S., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Thorn, C. F., Klein, T. E., & Lee, M. T. M. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. *Clinical Pharmacology and Therapeutics*, 93(2), 153–158. <https://doi.org/10.1038/clpt.2012.209>
- Hilmi, B. A., Asmahan, M. I., & Rosman, A. (2012). Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. *The Medical Journal of Malaysia*, 67(1), 125–126.
- Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., ... Chen, Y.-T. (2005). HLA-B\*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *Proceedings of the National Academy of Sciences*

- of the United States of America*, 102(11), 4134–4139.  
<https://doi.org/10.1073/pnas.0409500102>
- Illing, P. T., Vivian, J. P., Dudek, N. L., Kostenko, L., Chen, Z., Bharadwaj, M., ... McCluskey, J. (2012). Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. *Nature*, 486(7404), 554–558.  
<https://doi.org/10.1038/nature11147>
- Jansen, T. L., Richette, P., Perez-Ruiz, F., Tausche, A.-K., Guerne, P.-A., Punzi, L., ... Doherty, M. (2010). International position paper on febuxostat. *Clinical Rheumatology*, 29(8), 835–840. <https://doi.org/10.1007/s10067-010-1457-8>
- Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., ... JSAR research group. (2008). HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. *Pharmacogenomics*, 9(11), 1617–1622.  
<https://doi.org/10.2217/14622416.9.11.1617>
- Kim, E.-Y., Seol, J. E., Choi, J.-H., Kim, N.-Y., & Shin, J.-G. (2017). Allopurinol-induced severe cutaneous adverse reactions: A report of three cases with the HLA-B\*58:01 allele who underwent lymphocyte activation test. *Translational and Clinical Pharmacology*, 25(2), 63–66. <https://doi.org/10.12793/tcp.2017.25.2.63>
- Lam, M. P. S., Yeung, C. K., & Cheung, B. M. Y. (2013). Pharmacogenetics of allopurinol-making an old drug safer. *Journal of Clinical Pharmacology*, 53(7), 675–679.  
<https://doi.org/10.1002/jcph.67>
- Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *The Journal of the American Medical Association*, 279(15), 1200–1205.  
<https://doi.org/10.1001/jama.279.15.1200>
- Liao, P.-Y., & Lee, K. H. (2010). From SNPs to functional polymorphism: The insight into biotechnology applications. *Biochemical engineering journal*, 49(2), 149–158.  
<https://doi.org/10.1016/j.bej.2009.12.021>
- Lo, C., Nguyen, S., Yang, C., Witt, L., Wen, A., Liao, T. V., ... Palaniappan, L. (2020). Pharmacogenomics in asian subpopulations and impacts on commonly prescribed medications. *Clinical and translational science*, 13(5), 861–870.  
<https://doi.org/10.1111/cts.12771>
- Low, D. E., Nurul-Aain, A. F., Tan, W. C., Tang, J. J., Bakhtiar, M. F., Murad, S., ... Tang, M. M. (2020). HLA-B\*58: 01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia. *Pharmacogenetics and Genomics*, 30(7), 153–160.  
<https://doi.org/10.1097/FPC.0000000000000408>
- Muszkat, M. (2007). Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. *Clinical Pharmacology and Therapeutics*, 82(2), 215–218.  
<https://doi.org/10.1038/sj.clpt.6100142>

- Nassif, A., Bensussan, A., Dorothée, G., Mami-Chouaib, F., Bachot, N., Bagot, M., ... Roujeau, J.-C. (2002). Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. *The Journal of Investigative Dermatology*, *118*(4), 728–733. <https://doi.org/10.1046/j.1523-1747.2002.01622.x>
- Neefjes, J., Jongasma, M. L. M., Paul, P., & Bakke, O. (2011). Towards a systems understanding of MHC class I and MHC class II antigen presentation. *Nature Reviews. Immunology*, *11*(12), 823–836. <https://doi.org/10.1038/nri3084>
- Ng, C. Y., Yeh, Y.-T., Wang, C.-W., Hung, S.-I., Yang, C.-H., Chang, Y.-C., ... Taiwan Severe Cutaneous Adverse Reaction Consortium. (2016). Impact of the HLA-B(\*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. *The Journal of Investigative Dermatology*, *136*(7), 1373–1381. <https://doi.org/10.1016/j.jid.2016.02.808>
- PharmGKB. 2021. *Pathways Pharmacodynamics*. <https://www.pharmgkb.org/chemical/PA448320/pathway>
- Picard, D., Janela, B., Descamps, V., D’Incan, M., Courville, P., Jacquot, S., ... Musette, P. (2010). Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. *Science Translational Medicine*, *2*(46), 46ra62. <https://doi.org/10.1126/scitranslmed.3001116>
- Pichler, W. J. (2002). Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. *Current Opinion in Allergy and Clinical Immunology*, *2*(4), 301–305. <https://doi.org/10.1097/00130832-200208000-00003>
- Pichler, W. J. (2005). Direct T-cell stimulations by drugs—bypassing the innate immune system. *Toxicology*, *209*(2), 95–100. <https://doi.org/10.1016/j.tox.2004.12.014>
- Rollinson, V., Turner, R., & Pirmohamed, M. (2020). Pharmacogenomics for primary care: an overview. *Genes*, *11*(11). <https://doi.org/10.3390/genes11111337>
- Saksit, N., Nakkam, N., Konyoung, P., Khunarkornsiri, U., Tassaneeyakul, W., Chumworathayi, P., ... Tassaneeyakul, W. (2017). Comparison between the HLA-B\*58:01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions. *Journal of immunology research*, *2017*, 2738784. <https://doi.org/10.1155/2017/2738784>
- Somkrua, R., Eickman, E. E., Saokaew, S., Lohitnavy, M., & Chaiyakunapruk, N. (2011). Association of HLA-B\*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. *BMC Medical Genetics*, *12*, 118. <https://doi.org/10.1186/1471-2350-12-118>
- Sukasem, C., Jantararoungtong, T., Kuntawong, P., Puangpetch, A., Koomdee, N., Satapornpong, P., ... Rerkpattanapipat, T. (2016). HLA-B (\*) 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand. *Frontiers in pharmacology*, *7*, 186. <https://doi.org/10.3389/fphar.2016.00186>
- The Boston Collaborative Drug Surveillance Program, Boston University Medical Center. (1972). Excess of ampicillin rashes associated with allopurinol or hyperuricemia. A report from the Boston Collaborative Drug Surveillance Program, Boston

- University Medical Center. *The New England Journal of Medicine*, 286(10), 505–507. <https://doi.org/10.1056/NEJM197203092861002>
- Wang, Z., Luo, J., Fu, G., Wang, Z., & Wu, R. (2013). Stochastic modeling of systems mapping in pharmacogenomics. *Advanced Drug Delivery Reviews*, 65(7), 912–917. <https://doi.org/10.1016/j.addr.2013.03.004>
- Wu, R., Cheng, Y.-J., Zhu, L.-L., Yu, L., Zhao, X.-K., Jia, M., ... Cai, G.-J. (2016). Impact of HLA-B\*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. *Oncotarget*, 7(49), 81870–81879. <https://doi.org/10.18632/oncotarget.13250>
- Yang, C.-Y., Chen, C.-H., Deng, S.-T., Huang, C.-S., Lin, Y.-J., Chen, Y.-J., ... Chung, W.-H. (2015). Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. *JAMA internal medicine*, 175(9), 1550–1557. <https://doi.org/10.1001/jamainternmed.2015.3536>
- Yun, J., Adam, J., Yerly, D., & Pichler, W. J. (2012). Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. *Allergy*, 67(11), 1338–1346. <https://doi.org/10.1111/all.12008>
- Yun, James, Marcaida, M. J., Eriksson, K. K., Jamin, H., Fontana, S., Pichler, W. J., & Yerly, D. (2014). Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B\*58:01. *Journal of Immunology*, 192(7), 2984–2993. <https://doi.org/10.4049/jimmunol.1302306>
- Zanni, M. P., von Greyerz, S., Schnyder, B., Brander, K. A., Frutig, K., Hari, Y., ... Pichler, W. J. (1998). HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. *The Journal of Clinical Investigation*, 102(8), 1591–1598. <https://doi.org/10.1172/JCI3544>
- Zeng, M., Zhang, M., Liu, F., Yan, W., Kong, Q., & Sang, H. (2015). Drug eruptions induced by allopurinol associated with HLA-B\*5801. *Indian Journal of Dermatology, Venereology and Leprology*, 81(1), 43–45. <https://doi.org/10.4103/0378-6323.148566>